Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Inhaled Human Interferon Alfa 1b (GB05) in Healthy Adults
NCT06277167Phase 1Completed
- Sponsor
- Kexing Biopharm
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Antiviral Oral Spray in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Kexing Biopharm. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 2 more. Started Jan 2023; status: completed.
02
Drugs
Antiviral Oral Spray
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06277167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277167.